Cargando…

Engineering enhanced CAR T-cells for improved cancer therapy

Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milone, Michael C., Xu, Jie, Chen, Sai-Juan, Collins, McKensie A., Zhou, Jiafeng, Powell, Daniel J., Melenhorst, J. Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412433/ https://www.ncbi.nlm.nih.gov/pubmed/34485921 http://dx.doi.org/10.1038/s43018-021-00241-5

Ejemplares similares

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

Insulin signaling pathways in lepidopteran ecdysone secretion
por: Smith, Wendy A., et al.
Publicado: (2014)

Threading carbon nanotubes through a self-assembled nanotube
por: Ji, Mingyang, et al.
Publicado: (2019)

Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase
por: Durgin, Joseph S., et al.
Publicado: (2022)

Microemulsions: Breakthrough Electrolytes for Redox Flow Batteries
por: Barth, Brian A., et al.
Publicado: (2022)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
por: Long, Kristen B., et al.
Publicado: (2018)

Engineering CAR T cells for enhanced efficacy and safety
por: Wu, Yiqian, et al.
Publicado: (2022)

Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
por: Meng, Xianhui, et al.
Publicado: (2020)

Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds
por: Zajc, Charlotte U., et al.
Publicado: (2020)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors
por: Zhang, Hongru, et al.
Publicado: (2022)

Nano-Optogenetic Engineering of CAR T-cells for Precision Immunotherapy with Enhanced Safety
por: Nguyen, Nhung Thi, et al.
Publicado: (2021)

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing
por: Castellanos-Rueda, Rocío, et al.
Publicado: (2022)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Engineering CAR-T Cells for Improved Function Against Solid Tumors
por: Morgan, Michael A., et al.
Publicado: (2018)

Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
por: Bell, Matthew, et al.
Publicado: (2021)

318 Building A Better CAR: Improving CAR-T Trafficking in Cancer Therapy
por: Hong, Yeonsun, et al.
Publicado: (2022)

Engineering advanced logic and distributed computing in human CAR immune cells
por: Cho, Jang Hwan, et al.
Publicado: (2021)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

An engineered CARS substrate with giant field enhancement in crisscross dimer nanostructure
por: Zhang, Jia, et al.
Publicado: (2018)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Toward high-throughput engineering techniques for improving CAR intracellular signaling domains
por: Butler, Savannah E., et al.
Publicado: (2023)

Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
por: Schmidt, Paula, et al.
Publicado: (2021)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Engineering Axl specific CAR and SynNotch receptor for cancer therapy
por: Cho, Jang Hwan, et al.
Publicado: (2018)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
por: Wei, Jianshu, et al.
Publicado: (2020)

Recent advances in CAR-T cell engineering
por: Huang, Ruihao, et al.
Publicado: (2020)

CT103A, a forward step in multiple myeloma immunotherapies
por: Xu, Jie, et al.
Publicado: (2021)

Amino Acid Nanofibers Improve Glycemia and Confer Cognitive Therapeutic Efficacy to Bound Insulin
por: Lee, Aejin, et al.
Publicado: (2021)

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
por: Salzer, Benjamin, et al.
Publicado: (2020)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ksa2rd8mg7sli44q3g76pnqsg7